I
Illinois Retina Associates, S.C | Oak Park, IL
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Fluocinolone Acetonide
EYP-1901
Bevacizumab
Pemafibrate
ANX007
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 7 total trials
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Enrolling
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901
The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...
Enrolling
Geographic Atrophy
Drug: ANX007
Other: Sham Administration
A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uve...
Active, not recruiting
Uveitis, Posterior
Drug: Fluocinolone Acetonide Intravitreal Implant 0.18 mg
Trial sponsors
A
A
C
E
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems